BMY will pay BBIO $90 million in upfront cash.
Henry Kravis and his peers have been selling assets for top dollar as the global economy bounces back from fallout of the COVID-19 pandemic.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
| Website: | www.bridgebio.com |
| Main Phone: | +1 650 391-9740 |
| Address: | 421 Kipling Street |
| Address 2: | Suite 1430 |
| State: | CA |
| City / Town: | Palo Alto |
| Country: | US |
| Postal Code: | 94301 |
| Exchange: | NGS |
| CEO: | Neil Kumar |
| Employees: | 396 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
BMY will pay BBIO $90 million in upfront cash.
Henry Kravis and his peers have been selling assets for top dollar as the global economy bounces back from fallout of the COVID-19 pandemic.
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
